Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

196 ARTÍCULOS , VIENDO DEL 76 AL 90

Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review

Chaudhry A, Houlden H, Rizig M.

J Neurol Sci. 2020 Aug 15;415:116886. doi: 10.1016/j.jns.2020.116886. Epub 2020 May 11.

Orthostatic Blood Pressure Recovery Is Associated With the Rate of Cognitive Decline and Mortality in Clinical Alzheimer's Disease

de Heus RAA, de Jong DLK, Rijpma A, Lawlor BA, Olde Rikkert MGM, Claassen JAHR.

J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2169-2176. doi: 10.1093/gerona/glaa129.

Editorial: A Is for Amyloid

Selkoe DJ.

J Prev Alzheimers Dis. 2020;7(3):140-141. doi: 10.14283/jpad.2020.27.

Editorial: An Industry Perspective: Future of Anti-Amyloid Trials

Kramer LD.

J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.

Early Detection of Mild Cognitive Impairment (MCI) in Primary Care

Sabbagh MN, Boada M, Borson S, Chilukuri M, Dubois B, Ingram J, Iwata A, Porsteinsson AP, Possin KL, Rabinovici GD, Vellas B, Chao S, Vergallo A, Hampel H.

J Prev Alzheimers Dis. 2020;7(3):165-170. doi: 10.14283/jpad.2020.21.

Buccal Mucosa Biomarkers in Alzheimer's Disease

Avramouli A, Vlamos P.

Adv Exp Med Biol. 2020;1195:49-56. doi: 10.1007/978-3-030-32633-3_8.

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease

Khan S, Barve KH, Kumar MS.

Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429.

Exploring the Potential of Neuroproteomics in Alzheimer's Disease

Uddin MS, Kabir MT, Jakaria M, Sobarzo-Sánchez E, Barreto GE, Perveen A, Hafeez A, Bin-Jumah MN, Abdel-Daim MM, Ashraf GM.

Curr Top Med Chem. 2020;20(25):2263-2278. doi: 10.2174/1568026620666200603112030.

Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers

Mobed A, Hasanzadeh M.

Int J Biol Macromol. 2020 Oct 15;161:59-71. doi: 10.1016/j.ijbiomac.2020.05.257. Epub 2020 Jun 3.

Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials

Rafii MS.

CNS Drugs. 2020 Aug;34(8):785-794. doi: 10.1007/s40263-020-00740-6.

Advent of Proteomic Tools for Diagnostic Biomarker Analysis in Alzheimer's Disease

Singh M, Singh SP, Dubey PK, Rachana R, Mani S, Yadav D, Agarwal M, Agarwal S, Agarwal V, Kaur H.

Curr Protein Pept Sci. 2020;21(10):965-977. doi: 10.2174/1389203721666200615173213.

Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions

Bermejo-Pareja F, Del Ser T, Valentí M, de la Fuente M, Bartolome F, Carro E.

Alzheimers Dement. 2020 Aug;16(8):1196-1204. doi: 10.1002/alz.12107. Epub 2020 Jun 16.

The flash visual evoked potential-P2 and the detection of amnestic mild cognitive impairment: A review of empirical literature

Arruda JE, McInnis MC, Steele J.

Int J Psychophysiol. 2020 Sep;155:162-167. doi: 10.1016/j.ijpsycho.2020.05.012. Epub 2020 Jun 18.

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S.

J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134.

Towards a Redefinition of Cognitive Frailty

Mantovani E, Zucchella C, Schena F, Romanelli MG, Venturelli M, Tamburin S.

J Alzheimers Dis. 2020;76(3):831-843. doi: 10.3233/JAD-200137.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias